Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization - PubMed (original) (raw)
Comparative Study
Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization
B R Murphy et al. Vaccine. 1990 Oct.
Abstract
Formalin-inactivated (FI) RSV, purified F glycoprotein in alum, and RSV infection (intranasal) were compared for their immunogenicity, efficacy, and ability to enhance pulmonary histopathology during RSV infection 3 and 6 months following immunization by the intramuscular route. Purified influenza virus in alum was used as a control immunogen. At 1 month following immunization with one dose of purified F glycoprotein (5 micrograms), cotton rats developed levels of F antibodies (ELISA) higher than the other groups, but these antibodies had the lowest level of neutralizing activity, Little increase in antibody titre was seen following a second dose of FI-RSV or purified F vaccine given at 1 month. Animals that received 5 micrograms F, 0.5 microgram F, or were almost completely resistant to pulmonary RSV infection following challenge at 3 months, but were susceptible by 6 months. Animals immunized with 5 micrograms of purified F glycoprotein developed alveolar and bronchiolar histopathology following RSV challenge at 3 or 6 months which was comparable to that of animals immunized with FI-RSV. These levels significantly exceeded those in animals previously immunized with influenza A virus vaccine which exhibited little histopathology. Animals previously infected with RSV also developed bronchiolar, but not alveolar, histopathology suggesting that the bronchiolar histopathology seen in RSV challenged cotton rats is a normal component of the immune resolution of RSV infection. These results suggest that the immune response of cotton rats to immunoaffinity purified F glycoprotein can result in enhanced bronchiolar and alveolar histopathology following RSV challenge. Thus, caution should be exercised in studies in humans using a purified F glycoprotein subunit vaccine.
Comment in
- Immunogen-induced enhanced pulmonary histopathology in the RSV cotton rat model.
Hildreth SW, Baggs RR, Brownstein DG, Castleman WL, Paradiso PR. Hildreth SW, et al. Vaccine. 1993;11(6):689-90. doi: 10.1016/0264-410x(93)90328-u. Vaccine. 1993. PMID: 8322496 No abstract available.
Similar articles
- Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
Connors M, Collins PL, Firestone CY, Sotnikov AV, Waitze A, Davis AR, Hung PP, Chanock RM, Murphy BR. Connors M, et al. Vaccine. 1992;10(7):475-84. doi: 10.1016/0264-410x(92)90397-3. Vaccine. 1992. PMID: 1609551 - Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
Murphy BR, Sotnikov A, Paradiso PR, Hildreth SW, Jenson AB, Baggs RB, Lawrence L, Zubak JJ, Chanock RM, Beeler JA, et al. Murphy BR, et al. Vaccine. 1989 Dec;7(6):533-40. doi: 10.1016/0264-410x(89)90278-8. Vaccine. 1989. PMID: 2692334 - Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
Johnson TR, Graham BS. Johnson TR, et al. Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S46-57. doi: 10.1097/01.inf.0000108192.94692.d2. Pediatr Infect Dis J. 2004. PMID: 14730270 Review. - Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses.
Murphy BR, Prince GA, Collins PL, Van Wyke Coelingh K, Olmsted RA, Spriggs MK, Parrott RH, Kim HW, Brandt CD, Chanock RM. Murphy BR, et al. Virus Res. 1988 Aug;11(1):1-15. doi: 10.1016/0168-1702(88)90063-9. Virus Res. 1988. PMID: 2845680 Review.
Cited by
- Intranasal respiratory syncytial virus vaccine attenuated by codon-pair deoptimization of seven open reading frames is genetically stable and elicits mucosal and systemic immunity and protection against challenge virus replication in hamsters.
Levy M, Chen JW, Kaiser JA, Park HS, Liu X, Yang L, Santos C, Buchholz UJ, Le Nouën C. Levy M, et al. PLoS Pathog. 2024 May 13;20(5):e1012198. doi: 10.1371/journal.ppat.1012198. eCollection 2024 May. PLoS Pathog. 2024. PMID: 38739647 Free PMC article. - Mutations in the F protein of the live-attenuated respiratory syncytial virus vaccine candidate ΔNS2/Δ1313/I1314L increase the stability of infectivity and content of prefusion F protein.
Alamares-Sapuay J, Kishko M, Lai C, Parrington M, Delagrave S, Herbert R, Castens A, Swerczek J, Luongo C, Yang L, Collins PL, Buchholz UJ, Zhang L. Alamares-Sapuay J, et al. PLoS One. 2024 Apr 9;19(4):e0301773. doi: 10.1371/journal.pone.0301773. eCollection 2024. PLoS One. 2024. PMID: 38593167 Free PMC article. - Diversity and evolution of computationally predicted T cell epitopes against human respiratory syncytial virus.
Chen J, Tan S, Avadhanula V, Moise L, Piedra PA, De Groot AS, Bahl J. Chen J, et al. PLoS Comput Biol. 2023 Jan 10;19(1):e1010360. doi: 10.1371/journal.pcbi.1010360. eCollection 2023 Jan. PLoS Comput Biol. 2023. PMID: 36626370 Free PMC article. - Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2.
Park HS, Matsuoka Y, Luongo C, Yang L, Santos C, Liu X, Ahlers LRH, Moore IN, Afroz S, Johnson RF, Lafont BAP, Dorward DW, Fischer ER, Martens C, Samal SK, Munir S, Buchholz UJ, Le Nouën C. Park HS, et al. NPJ Vaccines. 2022 Jun 28;7(1):72. doi: 10.1038/s41541-022-00493-x. NPJ Vaccines. 2022. PMID: 35764659 Free PMC article. - Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses.
Gartlan C, Tipton T, Salguero FJ, Sattentau Q, Gorringe A, Carroll MW. Gartlan C, et al. Front Immunol. 2022 Apr 4;13:882972. doi: 10.3389/fimmu.2022.882972. eCollection 2022. Front Immunol. 2022. PMID: 35444667 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources